Literature DB >> 20122823

Reduced risk of oestrogen receptor positive breast cancer among peri- and post-menopausal women in Scotland following a striking decrease in use of hormone replacement therapy.

Katharine H Sharpe1, Paula McClements, Douglas I Clark, Joanne Collins, Anthea Springbett, David H Brewster.   

Abstract

Many countries report a decline in breast cancer incidence among peri- and post-menopausal women following a decline in HRT prescribing. To investigate recent Scottish incidence trends, European age-standardised incidence rates from 1997 to 2005 were stratified by method of first detection, ER status and age group. We developed change point models of the annual age-specific cases for the peri- and post-menopausal age groups and ER status using Poisson regression. In Scotland all HRT categories together show a 32.4% increase in the number of items dispensed in 1993-2000 followed by a striking 61.8% decline by 2007. The incidence rates of screen-detected tumours increased gradually in the 50-64 and 65-74 age groups. For the older age group this increase accelerated after 2003 corresponding to an extension of the age range of screening. For ER positive tumours in the 50-64 age group, age-standardised rates increased 31.5% from 1997 to 2000, followed by a statistically significant decrease of 11.2% by 2005 (change in slope=-0.0943, P<0.0001). We conclude that an overall incidence in the 50-64 age group declined since 2000 reflecting the sudden fall in HRT dispensed items and is largely accounted for by the decrease in ER positive tumour incidence. A longer term decline in ER negative tumours for this age group was pre-existing and is unaffected by the collapse in HRT prescribing. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20122823     DOI: 10.1016/j.ejca.2010.01.003

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

Review 1.  How to judge the association of postmenopausal hormone therapy and the risk of breast cancer.

Authors:  Ling Xu
Journal:  Front Med China       Date:  2010-08-05

2.  Incidence of breast cancer in the United States: current and future trends.

Authors:  William F Anderson; Hormuzd A Katki; Philip S Rosenberg
Journal:  J Natl Cancer Inst       Date:  2011-07-13       Impact factor: 13.506

3.  Impact of medicines regulatory risk communications in the UK on prescribing and clinical outcomes: Systematic review, time series analysis and meta-analysis.

Authors:  Christopher J Weatherburn; Bruce Guthrie; Tobias Dreischulte; Daniel R Morales
Journal:  Br J Clin Pharmacol       Date:  2019-12-16       Impact factor: 4.335

4.  β-Estradiol unmasks metabotropic receptor-mediated metaplasticity of NMDA receptor transmission in the female rat dentate gyrus.

Authors:  Nino Nebieridze; Xiao-Lei Zhang; Tamar Chachua; Libor Velíšek; Patric K Stanton; Jana Velíšková
Journal:  Psychoneuroendocrinology       Date:  2012-04-27       Impact factor: 4.905

5.  Divergent estrogen receptor-positive and -negative breast cancer trends and etiologic heterogeneity in Denmark.

Authors:  William F Anderson; Philip S Rosenberg; Lucia Petito; Hormuzd A Katki; Bent Ejlertsen; Marianne Ewertz; Birgitte B Rasmussen; Maj-Britt Jensen; Niels Kroman
Journal:  Int J Cancer       Date:  2013-06-13       Impact factor: 7.396

6.  Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004-2013): Amassing data from independent Western populations provide etiologic clues.

Authors:  Maeve Mullooly; Jeanne Murphy; Gretchen L Gierach; Paul M Walsh; Sandra Deady; Thomas I Barron; Mark E Sherman; Philip S Rosenberg; William F Anderson
Journal:  Eur J Cancer       Date:  2017-10-23       Impact factor: 9.162

7.  Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data.

Authors:  Ines Mesa-Eguiagaray; Sarah H Wild; Philip S Rosenberg; Sheila M Bird; David H Brewster; Peter S Hall; David A Cameron; David Morrison; Jonine D Figueroa
Journal:  Br J Cancer       Date:  2020-06-19       Impact factor: 7.640

8.  Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations.

Authors:  Thomas Goedecke; Daniel R Morales; Alexandra Pacurariu; Xavier Kurz
Journal:  Br J Clin Pharmacol       Date:  2017-12-20       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.